Biokine Therapeutics Overview
- Founded
- 2000
- Status
- Acquired/Merged
- Latest Deal Type
- Corporate
- Investors
- 6
Biokine Therapeutics General Information
Description
Developer of novel drugs designed to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. The company's novel drugs offers cancer treatment, mainly leukemia and myeloma, enabling healthcare industries to develop novel therapeutics against these devastating diseases.
Contact Information
Website
www.biokine.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- Weizmann Science Park
- PO Box: 2213
- Rehovot 76120
- Israel
+972 00-000-0000
Biokine Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Corporate | 03-Oct-2018 | Completed | Generating Revenue | |||
| 5. Merger/Acquisition | 00000 | Completed | Generating Revenue | |||
| 4. Grant | 18-Mar-2009 | 00.00 | 00000 | Completed | Generating Revenue | |
| 3. Later Stage VC | 10-Jan-2007 | 00000 | 00000 | Completed | Generating Revenue | |
| 2. Grant | $600K | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jul-2000 | Completed | Startup |
Biokine Therapeutics Patents
Biokine Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3090315-A1 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Pending | 15-May-2019 | 000000000 | |
| EP-3759074-A4 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Pending | 15-May-2019 | 0000000000 | |
| EP-3759074-A1 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Pending | 15-May-2019 | 000000000 | |
| US-20200369617-A1 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | Pending | 15-May-2019 | 000000000 | |
| ES-2818531-T3 | Small molecules to inhibit chemokine activity and / or cancer cell growth | Active | 17-Dec-2015 | C07D215/24 |
Biokine Therapeutics Executive Team (4)
Biokine Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amnon Peled Ph.D | Biokine Therapeutics | Co-Founder, Chief Executive Officer, Chief Scientific Officer & Board Member | 000 0000 |
| Anthony Stanton | Self | Board Member | 000 0000 |
| Assaf Segal | Self | Board Member | 000 0000 |
| H. Laurence Shaw MD | Self | Chairman | 000 0000 |
| Ofer Goldberg | Clal Biotechnology Industries | Board Member | 000 0000 |